FY2025 EPS Forecast for Lexeo Therapeutics Raised by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for Lexeo Therapeutics in a report issued on Tuesday, April 8th. Chardan Capital analyst G. Livshits now forecasts that the company will post earnings of ($3.06) per share for the year, up from their prior estimate of ($3.10). Chardan Capital currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09.

Several other equities research analysts also recently issued reports on the company. Royal Bank of Canada reduced their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, March 25th. Leerink Partners decreased their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, March 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of “Buy” and an average price target of $22.20.

Lexeo Therapeutics Trading Down 8.8 %

NASDAQ:LXEO opened at $1.98 on Friday. Lexeo Therapeutics has a 1-year low of $1.45 and a 1-year high of $19.50. The stock has a fifty day simple moving average of $3.33 and a 200 day simple moving average of $5.97. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $65.73 million, a price-to-earnings ratio of -0.63 and a beta of 1.52.

Institutional Investors Weigh In On Lexeo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in Lexeo Therapeutics by 107.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock valued at $577,000 after buying an additional 33,013 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares in the last quarter. State Street Corp lifted its holdings in Lexeo Therapeutics by 29.4% in the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after purchasing an additional 57,674 shares during the last quarter. Wellington Management Group LLP boosted its position in Lexeo Therapeutics by 134.8% during the third quarter. Wellington Management Group LLP now owns 51,892 shares of the company’s stock worth $469,000 after purchasing an additional 29,791 shares during the period. Finally, Jane Street Group LLC grew its holdings in Lexeo Therapeutics by 33.3% during the third quarter. Jane Street Group LLC now owns 35,677 shares of the company’s stock valued at $323,000 after purchasing an additional 8,918 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.